Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
复制标题
DOI：
10.1016/j.canlet.2008.01.015
复制
发表时间：
2008-06
期刊：
影响因子：
9.7
通讯作者：
Y. Miyoshi;M. Kurosumi;J. Kurebayashi;N. Matsuura;M. Takahashi;E. Tokunaga;C. Egawa;N. Masuda;Seung Jin Kim;M. Okishiro;T. Yanagisawa;S. Ueda;T. Taguchi;Y. Tamaki;S. Noguchi
中科院分区：
文献类型：
--
作者：
Y. Miyoshi;M. Kurosumi;J. Kurebayashi;N. Matsuura;M. Takahashi;E. Tokunaga;C. Egawa;N. Masuda;Seung Jin Kim;M. Okishiro;T. Yanagisawa;S. Ueda;T. Taguchi;Y. Tamaki;S. Noguchi
表阿霉素通过与拓扑异构酶II α（TOP 2A）结合并诱导DNA双链断裂来发挥其抗肿瘤作用。BRCA 1参与这些断裂的修复。我们研究了TOP 2A或BRCA 1免疫组化表达与108例原发性乳腺癌的病理反应之间的关系，这些乳腺癌接受了以表柔比星为基础的治疗方案。TOP 2A阳性患者的pCR（病理完全缓解）率（17%）显著（P<0.005）高于TOP 2A阴性患者（2%），而BRCA 1阴性患者的pCR率（11%）不显著高于BRCA 1阳性患者（5%）。TOP 2A阳性且BRCA 1阴性的pCR率（30%）明显高于TOP 2A阴性且BRCA 1阳性的pCR率（3%; P<0.05），或TOP 2A阴性且BRCA 1阴性的pCR率（0%; P<0.005）。TOP 2A阳性和BRCA 1阴性表型与对表柔比星方案的良好反应相关。
Epirubicin exerts its anti-tumor effect through binding to topoisomerase IIalpha (TOP2A) and inducing DNA double-strand breaks. BRCA1 is involved in the repair of these breaks. We investigated the relationship between TOP2A or BRCA1 immunohistochemical expression and pathological response in 108 primary breast cancers treated with epirubicin-based regimens. The pCR (pathological complete response) rate for TOP2A-positive (17%) was significantly (P<0.005) higher than for TOP2A-negative (2%), while the pCR rate for BRCA1-negative (11%) was non-significantly higher than for BRCA1-positive (5%). The pCR rate of TOP2A-positive and BRCA1-negative (30%) was significantly higher than for TOP2A-negative and BRCA1-positive (3%; P<0.05), or TOP2A-negative and BRCA1-negative (0%; P<0.005). The TOP2A-positive and BRCA1-negative phenotype associates with a favorable response to epirubicin-based regimens.